Ideal Marker for Targeted Axillary Dissection (IMTAD)

University Hospital Ostrava

Status: Completed

Conditions: Breast Cancer

Treatments: Procedure: Targeted axillary dissection

Study type: Observational

Funder types: Other

Identifiers

NCT04580251

CHIR-05-IMTAD

Details and patient eligibility

About

A multicentre prospective comparative study, comparing the use of various markers (magnetic marker Magseed, iodine seed 125I, carbon suspension) for marking a pathological lymph node in patients with breast carcinoma prior to neoadjuvant therapy and subsequent surgical treatment consisting of targeted axillary dissection.

Full description

There are two basic aims of the study

1. Prospective comparison of the reliability and accuracy of individual markers used for marking of a pathological axillary lymph node with subsequent targeted axillary dissection.
2. Comparison of the number of complications during localizing and detection of individual markers and postoperative complications.

In individual collaborating centers, these markers are commonly used in clinical practice for marking of a pathological lymph node in patients with breast carcinoma. The usual standard of practice and treatment will not be changed in any way; the patients will only be prospectively followed. The study will bring an answer to the question of which marker is the best for marking lymph nodes.

Apart from the basic demographic and other data (patient age, side of the body, size and characteristics of the tumor (typing, grading, staging), type and time of surgery, the incidence of complications during implantation or detection of the marker, number of lymph nodes, complications after surgery, and the final histological findings, also the following outcome measures will be observed:

• depth of marker implantation (measured in mm)
• marker migration (measured in mm)
• success-rate of resection of the marked lymph node - assessment, whether the lymph node was removed (yes/no) using the respective marker, expressed in percent of successful removal for the respective marker
• time from localizing the pathological lymph node using the marker to surgery (measured n days)

Enrollment: 100 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• diagnosis of breast cancer, confirmed with a biopsy
• indication of neoadjuvant therapy
• biopsy of pathologically enlarged axillary lymph node and marking of the lymph node using one of the markers before neoadjuvant chemotherapy
• surgical treatment after neoadjuvant chemotherapy (targeted axillary dissection)

Exclusion criteria

• refusal to participate in the study
• another treatment protocol, which does not include targeted axillary dissection

Trial design

100 participants in 3 patient groups

Magnetic marker Magseed

Description:

Patients in whom the magnetic marker Magseed is used will be enrolled in this study arm and will undergo targeted axillary dissection.

Treatment:

Procedure: Targeted axillary dissection

Iodine seed 125I marker

Description:

Patients in whom the iodine seed 125I marker is used will be enrolled in this study arm and will undergo targeted axillary dissection.

Treatment:

Procedure: Targeted axillary dissection

Carbon suspension

Description:

Patients in whom the carbon suspension marker is used will be enrolled in this study arm and will undergo targeted axillary dissection.

Treatment:

Procedure: Targeted axillary dissection